GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (BOM:500259) » Definitions » Cash per Share

Lyka Labs (BOM:500259) Cash per Share : ₹2.83 (As of Mar. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lyka Labs Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Lyka Labs's Cash per Share for the quarter that ended in Mar. 2024 was ₹2.83.


Lyka Labs Cash per Share Historical Data

The historical data trend for Lyka Labs's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Cash per Share Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.25 0.97 1.65 2.83

Lyka Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 - 1.80 - 2.83

Lyka Labs Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Lyka Labs's Cash per Share for the fiscal year that ended in Mar. 2024 is calculated as:

Lyka Labs's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyka Labs  (BOM:500259) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


Lyka Labs Cash per Share Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs (BOM:500259) Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment viz. pharmaceuticals. The Company has presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs (BOM:500259) Headlines

No Headlines